AEN’s dnaJP1 Positive Results on Rheumatoid Arthritis’ Treatment. AEN, X-Treme Hot Stock Alert by DrStockPick.com
Dr Stock Pick HOT News & Alerts!
_______________________________________
FREE Daily Stock Alerts From DrStockPick.com
_______________________________________
Friday November 13, 2009
DrStockPick.com Stock Report!
**************************************************************
AEN, Adeona Pharmaceuticals, Inc.
AEN is a specialty pharmaceutical company dedicated to the awareness, diagnosis, prevention and treatment of zinc deficiency and chronic copper toxicity in the mature population. Using AEN’s proprietary, modified oral zinc delivery technologies, AEN is preparing to initiate the first clinical trial of oral zinc therapy for the once-a-day dietary management of Alzheimer’s disease and mild cognitive impairment. AEN is also developing a number of late-stage clinical drug candidates for the treatment of rheumatoid arthritis and multiple sclerosis.
AEN’s Oral dnaJP1 is an orally active epitope-specific immunotherapeutic molecule derived from a family of heat shock proteins that contribute to autoimmune inflammation in rheumatoid arthritis patients.
A Study results of a 160-patient, six-month, double-blind, placebo-controlled Phase 2 clinical trial using AEN’s dnaJP1 for the treatment of rheumatoid arthritis shows Positive Results and holds promise for patients with this disease.
AEN is actively seeking worldwide corporate partners interested in assisting in the further development and commercialization of this novel and potentially important new therapeutic approach for rheumatoid arthritis.
More about AEN at www.adeonapharma.com
AEN, X-Treme Hot Stock Alert by DrStockPick.com
***********Advertisement***********
******************************
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. (read more) . Rule 17B requires disclosure of payment for investor relations.
Tags: Adeona Pharmaceuticals, AEN, Alzheimer's disease, autoimmune inflammation, chronic copper toxicity, dnaJP1, epitope-specific immunotherapeutic molecule, rheumatoid arthritis, zinc deficiency
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
